National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Atezolizumab (Tecentriq®) in combination with carboplatin and etoposide is indicated for first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

NCPE Assessment Process Complete
Rapid Review commissioned: 19/08/2019
Rapid Review completed 16/09/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 18/09/2019
Pre-submission consultation with Applicant 16/12/2019
Submission received from Applicant 08/05/2020
Current status NCPE assessment ongoing